Ameloblastoma
6
2
2
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
5 treatments under study, led by Dabrafenib
Research Leaders
6 sponsors active, led by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 6 trials
100.0%
+13.4% vs benchmark
17%
1 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (6)
Virtual Lesion Segmentation and Mandibular Ameloblastoma Radiographic Safety Margin
Neoadjuvant Therapy With Conservative Surgery vs. Up-front Conservative Surgery for BRAF V600E-Mutated Ameloblastoma
Effect of Tetracycline Socked Pack on Acceleration of Healing During Marsupialization
Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma
Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant Ameloblastoma
Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma
Research Network
Common Treatments
- Dabrafenib3
- Trametinib2
- Dabrafenib And Trametinib Combination1
- Tetracyclin1
- Virtual Lesion Segmentation For Mandibular Ameloblastoma1
Active Sponsors
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University2
- Shandong University1
- Alexandria University1
- Stanford University1
- Minia University1
Top Investigators
Stanford University
Shandong University School of Stomatology
Faculty of Dentistry, Minia University
Faculty of Dentistry, Alexandria University, Alexandria, Alexandria
Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Related Conditions
- Braf V600e Mutation Positive1
- Braf Gene Mutation1